TetraLogic Pharmaceuticals Corp. and Merck have entered an oncology clinical study collaboration to evaluate the safety and efficacy of birinapant, TetraLogic’s SMAC-mimetic, in combination with KEYTRUDA (pembrolizumab), Merck’s anti-PD-1 therapy, in patients with relapsed or refractory solid tumors. The Phase I study is expected to begin in late 2015. KEYTRUDA and birinapant target different elements of cancer’s block against the immune system. The collaboration is based on preclinical data th...